Increased Endometriosis Awareness Are Expected To Support Endometriosis Treatment Market Growth

 

Endometriosis Treatment

Endometriosis is a painful medical condition in which the endometrium, the tissue that lines the inner part of the uterus, grows outside the uterus. Endometriosis tissue can be found in the fallopian tubes, ovaries, and pelvic tissue. Endometrial tissue that has been displaced behaves normally in endometriosis, thickening, breaking down, and eventually bleeding as it does during every menstrual cycle. Because there is no other way for the displaced tissue to exit the body, it becomes trapped outside the uterus. Endometriosis is caused by the involvement of the ovaries, which results in the formation of cysts known as endometriomas. As a result, the surrounding tissues develop an adhesion (abnormal bands of fibrous tissue that cause pelvic organs and tissues to stick together) or scar tissue near the ovaries.

 

Increasing research activities for the development of new drugs for the global Endometriosis Treatment Market will be a major driver of market growth during the forecast period. For example, in 2017, AbbVie, a biopharmaceutical company, in collaboration with Neurocrine Biosciences Inc, submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for elagolix, a new drug. It is an orally administered gonadotropin releasing hormone antagonist that is being studied for the treatment of endometriosis pain. The introduction of new products by manufacturers is also expected to drive the global endometriosis treatment market. For example, in 2018, LASCO distributors, in collaboration with Bayer Healthcare, launched the new drug visanne, which is indicated for the treatment of endometriosis.

 

Other factors such as increased endometriosis prevalence, a robust pipeline, and increased endometriosis awareness are expected to support Endometriosis Treatment Market growth. For example, Triptoreline, which is sponsored by the University Hospital of Rouen, is in Phase 3 Clinical Trials; Triptoreline cures deep endometriosis in the rectum. Myovant Sciences has Relugolix in Phase 3 Clinical Trials; Relugolix stops non-menstrual pelvic pain. Indocyannine Green, sponsored by University Hospital, is in Phase 4 Clinical Trials; Indocyannine Green treats recto vaginal endometriosis. Dienogest, sponsored by the University Of Hong Kong, is in Phase 4 Clinical Trials; dienogest prevents endometriosis cyst recurrence. Merional, which is sponsored by Cario University, is in phase 3 clinical trials; Merional regulates intrauterine insemination cycles in endometriosis-affected women.

Comments

Popular posts from this blog

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy

The Isocyanates Market to Witness Robust Growth in North America and Asia Pacific

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins